Case Reports in Clinical Medicine

Vol.4 No.4(2015), Paper ID 55778, 6 pages

DOI:10.4236/crcm.2015.44028

 

Trastuzumab Re-Introduction with FOLFIRI for Treatment of HER2 Overexpression-Advanced Gastric Adenocarcinoma Following Failure of Other Trastuzumab-Based Chemotherapy Regimens

 

Olivier Dubreuil, Aziz Zaanan, Olivier Pellerin, Jean-Baptiste Bachet, Philippe Rougier, Julien Taieb

 

Gastro-Enterology and Digestive Oncology Unit, Pitie Salpetriere Hospital, Paris, Farnce
Digestive Oncology Unit, European Georges Pompidou Hospital, Paris, France
Paris-Descartes Medical University, INSERM U970, Interventionnal Radiology, European Georges Pompidou Hospital, Paris, France
Gastro-Enterology and Digestive Oncology Unit, Pitie Salpetriere Hospital, Paris, Farnce
Digestive Oncology Unit, European Georges Pompidou Hospital, Paris, France
Digestive Oncology Unit, European Georges Pompidou Hospital, Paris, France

 

Copyright © 2015 Olivier Dubreuil, Aziz Zaanan, Olivier Pellerin, Jean-Baptiste Bachet, Philippe Rougier, Julien Taieb et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

 

How to Cite this Article


Dubreuil, O. , Zaanan, A. , Pellerin, O. , Bachet, J. , Rougier, P. and Taieb, J. (2015) Trastuzumab Re-Introduction with FOLFIRI for Treatment of HER2 Overexpression-Advanced Gastric Adenocarcinoma Following Failure of Other Trastuzumab-Based Chemotherapy Regimens. Case Reports in Clinical Medicine, 4, 131-136. doi: 10.4236/crcm.2015.44028.

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.